Is Sun Pharma Advanced Research Company Ltd (SPARC) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company .

Is Sun Pharma Advanced Research Company Ltd (SPARC) undervalued or overvalued?

The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Sun Pharma Advanced Research Company Ltd (SPARC) share price return in the past 10 years?

Sun Pharma Advanced Research Company Ltd share price has declined -6.6% annually (CAGR) over the past ten years.

Is Sun Pharma Advanced Research Company Ltd (SPARC) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Sun Pharma Advanced Research Company Ltd (SPARC)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sun Pharma Advanced Research Company Ltd (SPARC) on 17-Apr-2026 16:59:59 at 16:59 is 147.90.

What is the market cap of Sun Pharma Advanced Research Company Ltd (SPARC)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Sun Pharma Advanced Research Company stood at Rs. 4799.67 Cr.

What is the P/E ratio of Sun Pharma Advanced Research Company?

The latest standalone P/E ratio of Sun Pharma Advanced Research Company as of 17-Apr-2026 is 0.00.

What is the P/B ratio of Sun Pharma Advanced Research Company Ltd (SPARC)?

The latest standalone P/B ratio of Sun Pharma Advanced Research Company Ltd (SPARC) as of 17-Apr-2026 is -11.18.

What is the 52-week high and low of Sun Pharma Advanced Research Company Ltd (SPARC)?

The 52-week high of Sun Pharma Advanced Research Company Ltd (SPARC) is Rs. 204.25 and the 52-week low is Rs. 108.20.

What is the TTM revenue of Sun Pharma Advanced Research Company Ltd (SPARC)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Advanced Research Company is Rs. 53.14 (Cr.).

Sun Pharma Advanced Research Company Ltd (SPARC) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Sun Pharma Advanced Research Company Ltd (SPARC)
Brand: Sun Pharma Advanced Research Company

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-71.4%	-94.7%	-113.1%	-60%	-179%	-254.1%	-225.6%	-69.4%	-112.9%	-321.2%	-
Value Creation Index ⓘ	-6.3	-8.0	-9.4	-5.3	NA	NA	NA	-6.1	-9.4	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	161	181	78.3	183	76.8	253	137	239	75.6	71.8	53
Sales YoY Gr.	-	12.2%	-56.8%	133.7%	-58%	229.3%	-45.7%	74%	-68.4%	-5%	-
Adj EPS ⓘ	-3	-4.9	-9.3	-5.5	-12	-5.9	-7.6	-6.9	-12	-10.6	-8.3
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	1.2	6.4	3.7	11.3	-0.7	-6.4	-7.5	15.8	3.9	-6.8	-13.2
Adj Net Profit ⓘ	-69.8	-120	-234	-144	-314	-154	-207	-223	-389	-345	-270
Cash Flow from Ops. ⓘ	-44.2	-128	-183	-172	-211	-152	-208	-69.1	-429	-362	-
Debt/CF from Ops. ⓘ	-1.3	-0	-0	-0	-0.3	-1.5	-0.4	-0	-0.1	-0.7	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-8.6%	-1.4%	-19.4%	-5%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-221.1%	NA	NA	-276.6%
Share Price	-6.6%	-2.1%	-8.8%	-1.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-106.1	-126.7	-136.6	-60	-226	164.6	301.5	-81.8	-121.9	720	83
Op. Profit Mgn % ⓘ	-39	-67.7	-310	-79.1	-397.7	-53.4	-135.5	-88.7	-530.7	-453.6	-431
Net Profit Mgn % ⓘ	-43.3	-66.5	-299.2	-78.9	-408.3	-60.8	-150.5	-93.2	-514.5	-480.4	-507.5
Debt to Equity ⓘ	1.9	0	0	0	-3.6	-1.4	-0.4	0	0.4	-1.2	-
Working Cap Days ⓘ	163	210	641	254	554	175	351	339	1,154	918	60
Cash Conv. Cycle ⓘ	-130	-170	-113	-272	-254	-119	-60	-85	-79	-126	-1,662

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 83.00%

Sales growth has been subdued in last 3 years -19.44%

Sales growth is not so good in last 4 quarters at -15.17%

	Standalone	Consolidated
TTM EPS (₹)	-8.3	-8.3
TTM Sales (₹ Cr.)	53.1	53.1
BVPS (₹) ⓘ	-13.2	-13.1
Reserves (₹ Cr.) ⓘ	-462	-458
P/BV ⓘ	-11.18	-11.29
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	108.20 / 204.25
All Time Low / High (₹)	38.44 / 593.93
Market Cap (₹ Cr.)	4,800
Equity (₹ Cr.)	32.5
Face Value (₹)	1
Industry PE ⓘ	32.7

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	161	181	78	183	77	253	137	239	76	72
Operating Expenses ⓘ +	224	304	321	334	387	388	324	453	479	399
Manufacturing Costs	31	34	37	23	36	214	139	186	146	121
Material Costs	0	0	0	0	0	0	0	0	0	0
Employee Cost	57	84	101	81	93	92	98	107	119	109
Other Costs ⓘ	137	185	183	230	258	82	87	160	214	169
Operating Profit ⓘ	-63	-123	-243	-151	-310	-135	-187	-214	-404	-327
Operating Profit Margin (%)	-39.2%	-67.8%	-310.0%	-82.7%	-403.0%	-53.4%	-136.0%	-89.6%	-534.0%	-456.0%
Other Income ⓘ +	3	14	5	14	10	5	7	11	29	2
Exceptional Items ⓘ	0	0	49	0	0	0	0	0	0	0
Interest ⓘ	2	2	0	0	3	11	13	8	2	9
Depreciation ⓘ	8	8	8	8	9	11	10	12	12	11
Profit Before Tax ⓘ	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345
Tax ⓘ	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345
PAT Margin (%)	-43.4%	-65.8%	-251.0%	-79.5%	-406.0%	-59.8%	-148.0%	-93.2%	-513.0%	-481.0%
Adjusted EPS (₹)	-3.0	-4.8	-7.9	-5.6	-11.9	-5.8	-7.5	-6.9	-12.0	-10.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	30	158	93	296	-19	-168	-203	513	125	-221
Share Capital ⓘ	24	25	25	26	26	26	27	32	32	32
Reserves ⓘ	6	133	68	270	-45	-194	-230	480	92	-253
Debt +	55	3	2	1	66	193	0	0	47	258
Long Term Debt	3	2	2	1	6	113	0	0	0	100
Short Term Debt	52	0	0	0	60	80	0	0	47	158
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	58	94	102	83	159	91	72	148	150	124
Others Liabilities ⓘ	23	21	116	18	66	114	411	169	165	167
Total Liabilities ⓘ	167	277	313	398	273	230	280	830	486	329
Fixed Assets
Net Fixed Assets ⓘ +	70	69	52	58	104	91	92	106	103	95
Gross Block	107	77	67	80	136	123	133	146	152	153
Accumulated Depreciation	37	8	15	23	32	32	41	40	49	57
CWIP ⓘ	1	1	3	24	32	5	26	27	44	54
Investments ⓘ	0	10	108	211	8	6	12	291	2	0
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	9	39	18	10	16	18	28	33	16	16
Cash Equivalents ⓘ	13	70	1	1	0	9	1	112	155	1
Others Assets ⓘ	74	87	131	95	112	101	121	262	167	162
Total Assets ⓘ	167	277	313	398	273	230	280	830	486	329

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-44	-128	-183	-172	-211	-152	-208	-69	-429	-362
PBT ⓘ	-70	-119	-246	-145	-312	-151	-203	-223	-388	-345
Adjustment ⓘ	9	-1	4	-22	9	49	17	7	-11	19
Changes in Working Capital ⓘ	30	13	20	-0	102	-48	-26	141	-26	-47
Tax Paid ⓘ	-14	-21	-10	-5	-10	-2	5	5	-4	11
Cash Flow From Investing Activity ⓘ +	-13	-7	-105	-102	155	2	-29	-548	391	158
Capex	-12	-8	-18	-13	-54	-1	-25	-15	-26	-10
Net Investments	-0	-9	-88	-93	209	3	-5	-535	395	153
Others ⓘ	-1	11	1	3	0	0	0	2	22	15
Cash Flow From Financing Activity ⓘ +	51	194	224	274	55	159	229	617	43	201
Net Proceeds from Shares ⓘ	2	250	133	367	-0	0	167	0	0	0
Net Proceeds from Borrowing ⓘ	-1	-1	0	-1	0	106	-113	0	0	100
Interest Paid ⓘ	-2	-3	-0	-0	-2	-8	-14	-8	-2	-8
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	51	-52	91	-92	57	61	189	625	44	109
Net Cash Flow ⓘ	-7	60	-63	0	0	9	-8	-1	4	-4

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-109.16	-127.4	-156.84	-74.72	N/A	N/A	N/A	-143.72	-121.73	N/A
ROCE (%)	-71.37	-94.66	-113.05	-59.95	N/A	N/A	N/A	-69.44	-112.88	N/A
Asset Turnover Ratio	1.03	0.82	0.27	0.51	0.23	1.01	0.54	0.43	0.11	0.18
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	33	48	132	28	62	24	60	46	117	80
Inventory Days	0	0	0	0	0	0	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	0

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

2006: SPARC is founded in Vadodara, India
2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
2012: 1st NDA filed with USFDA for Elepsia XR
2012: Raised Rs. 200 crore through Rights Issue
2013: Filed NDA for Xelpros with USFDA
2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
2015: Entered into research collaboration in the field of Oncology with US University
2015: Launched Bevetex (PICS) in India
2016: Raised Rs. 250 crore through Rights Issue
2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Sun Pharma Advanced Research Company Ltd (SPARC) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Sun Pharma Adv. Res Share Price